# Edwards Lifesciences Corporation (EW) stock price

URL: https://funkfolio.com/stock/EW

> Edwards Lifesciences Corporation (EW) trades at $107.37, is worth $61.82B, is priced at 62.5× earnings and scores 63/100.

---

## Edwards Lifesciences Corporation (EW)

Edwards Lifesciences Corporation (EW) is a healthcare company (medical devices) based in the United States. The share price is $107.37, up 0.24% on the day, which values the company at $61.82B. Price as of 17 Nov 2026, 17:36 UTC, from Yahoo Finance.

### Key facts

- **Share price:** $107.37 +0.24% today
- **Market value:** $61.82B
- **P/E ratio:** 62.5× last 12 months
- **Forward P/E:** 31.8×
- **Funk Score:** 63/100
- **Against its own history:** Above its usual price usual price $87.52
- **200-week average:** $80.10 34% above
- **Sector:** Healthcare

Figures as of 17 Nov 2026, 17:36 UTC. Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

### Edwards Lifesciences Corporation in more detail

EW trades at 62.5× its last twelve months' earnings, 31.8× next year's expected earnings, 9.3× sales. Measured against its own history, the price is 23% above what its usual multiples would imply ($87.52) — above its usual price. It sits 34% above its 200-week average of $80.10.

Over the last five fiscal years Edwards Lifesciences Corporation has compounded revenue 6.7% a year, earnings per share 7.1% a year, free cash flow 15.6% a year. Its Funk Score is 63 out of 100 (financial strength 9.3, profitability 7.5, growth 5.9, value 2.3, each out of 10).

In its favour: Altman Z in the safe zone; Share count keeps falling. Worth checking: Gross margin is shrinking.

9 of the superinvestors tracked here hold EW, including David Rolfe (3.1% of the portfolio), Howard Gleicher (1.6% of the portfolio), Brandon Haley (0.7% of the portfolio).

### Superinvestors holding EW

9 of the investors tracked here report a position in their latest 13F filing.

- [David Rolfe Wedgewood Partners](https://funkfolio.com/gurus/david-rolfe) 3.09% of portfolio · $14.9M · trimmed · Q2 2026
- [Howard Gleicher Aristotle Capital Management](https://funkfolio.com/gurus/howard-gleicher) 1.60% of portfolio · $700.7M · trimmed · Q3 2026
- [Brandon Haley Holocene Advisors](https://funkfolio.com/gurus/brandon-haley) 0.65% of portfolio · $284M · added · Q2 2026
- [Steve Cohen Point72 Asset Management](https://funkfolio.com/gurus/steve-cohen) 0.25% of portfolio · $160.5M · trimmed · Q2 2026
- [Israel Englander Millennium Management](https://funkfolio.com/gurus/israel-englander) 0.22% of portfolio · $324.3M · added · Q2 2026
- [Ken Griffin Citadel Advisors](https://funkfolio.com/gurus/ken-griffin) 0.21% of portfolio · $361.7M · added · Q2 2026
- [Primecap team Primecap Management](https://funkfolio.com/gurus/primecap) 0.19% of portfolio · $309.4M · added · Q3 2026
- [Baillie Gifford team Baillie Gifford & Co](https://funkfolio.com/gurus/baillie-gifford) 0.14% of portfolio · $150.2M · added · Q3 2026
- [Ron Baron Baron Capital (BAMCO)](https://funkfolio.com/gurus/ron-baron) 0.06% of portfolio · $38.5M · added · Q3 2026

### Health Care companies of similar size

- [Takeda Pharmaceutical TAK](https://funkfolio.com/stock/TAK)
- [Cencora COR](https://funkfolio.com/stock/COR)
- [Boston Scientific BSX](https://funkfolio.com/stock/BSX)
- [Cardinal Health CAH](https://funkfolio.com/stock/CAH)
- [argenx ARGX](https://funkfolio.com/stock/ARGX)
- [Becton, Dickinson BDX](https://funkfolio.com/stock/BDX)
- [IDEXX Laboratories IDXX](https://funkfolio.com/stock/IDXX)
- [Medline MDLN](https://funkfolio.com/stock/MDLN)
- [Humana HUM](https://funkfolio.com/stock/HUM)
- [Agilent Technologies A](https://funkfolio.com/stock/A)
- [Teva Pharmaceutical Industries TEVA](https://funkfolio.com/stock/TEVA)
- [BeOne Medicines ONC](https://funkfolio.com/stock/ONC)

Side by side: [EW vs ARGX (Edwards Lifesciences Corporation vs argenx)](https://funkfolio.com/compare/argx-vs-ew) [EW vs BDX (Edwards Lifesciences Corporation vs Becton, Dickinson)](https://funkfolio.com/compare/bdx-vs-ew) [EW vs CAH (Edwards Lifesciences Corporation vs Cardinal Health)](https://funkfolio.com/compare/cah-vs-ew) [EW vs BSX (Edwards Lifesciences Corporation vs Boston Scientific)](https://funkfolio.com/compare/bsx-vs-ew) [EW vs IDXX (Edwards Lifesciences Corporation vs IDEXX Laboratories)](https://funkfolio.com/compare/ew-vs-idxx)

[All health care companies by market value](https://funkfolio.com/companies/sector/health-care) [Largest companies in the United States](https://funkfolio.com/companies/country/united-states) [All stocks A–Z](https://funkfolio.com/stocks)

### Edwards Lifesciences Corporation (EW): questions and answers

**What is EW's P/E ratio?**

Edwards Lifesciences Corporation trades at 62.5× its last twelve months' earnings and 31.8× next year's expected earnings. At its fiscal year-ends over the past 18 years the P/E ranged from 10.6× to 70.2×, with a median of 35.8×.

**What is EW's PEG ratio?**

Edwards Lifesciences Corporation's PEG ratio is 2.36 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.

**What is Edwards Lifesciences Corporation's market cap?**

Edwards Lifesciences Corporation is valued at $61.82B at a share price of $107.37.

**Is EW overvalued or undervalued?**

Against its own history, EW is above its usual price: the price is 23% above the $87.52 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

**Is EW above its 200-week moving average?**

Yes. EW is 34.0% above its 200-week average of $80.10. Long-term investors watch that line because strong companies rarely trade below it for long.

**How fast is Edwards Lifesciences Corporation growing?**

Over the last five fiscal years Edwards Lifesciences Corporation's revenue grew 6.7% a year and its earnings per share 7.1% a year; over ten years revenue grew 9.3% a year.

### Learn to read these numbers

[All stocks guides →](https://funkfolio.com/learn/stocks)

- [Altman Z-score: formula, zones and where it fails](https://funkfolio.com/learn/stocks/altman-z-score)

  The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- [Analyst price targets and ratings: what they mean](https://funkfolio.com/learn/stocks/analyst-price-targets)

  An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- [Free cash flow and FCF yield explained](https://funkfolio.com/learn/stocks/free-cash-flow)

  Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.

### Cite this page

Funkfolio, “Edwards Lifesciences Corporation (EW) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/EW

Underlying data: Yahoo Finance; company filings with the SEC.
